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A B S T R A C T
Neglected tropical diseases (NTDs) constitute a group of infectious diseases prevalent in countries with tropical
and subtropical climate that affect the poorest individuals and produce high chronic disability associated with
serious problems for the health system and socioeconomic development. Chagas disease or American trypano-
somiasis is included on the NTDs list. However, even though this disease affects more than 10 million people,
mostly in Latin America, causing the death of over 10,000 people every year, only two drugs are approved for its
treatment, benznidazole and nifurtimox. These antiparasitic agents were developed almost half a century ago
and present several biopharmaceutical disadvantages such as low aqueous solubility and permeability limiting
their bioavailability. In addition, both therapeutic agents are available only as tablets and a liquid pediatric
formulation is still lacking. Therefore, novel pharmaceutical strategies to optimize the pharmacotherapy of
Chagas disease are urgently required. In this regard, nanotechnological approaches may be a crucial alternative
for the delivery of both drugs ensuring an effective pharmacotherapy although the successful bench-to-bedside
translation remains a major challenge. The present work reviews in detail the formulation and in-vitro/in-vivo
analysis of different nanoformulations of nifurtimox and benznidazole in order to enhance their solubility,
dissolution, bioavailability and trypanocidal activity.
1. Introduction
Neglected tropical diseases (NTDs) are a group of infectious diseases
produced by bacteria, virus and parasites that prevail in tropical and
subtropical conditions in 149 countries affecting more than one billion
people (one-seventh of the world's population) and putting nearly one
billion at risk (WHO, 2015).
The term “neglected” is due to such diseases have been largely elimi-
nated in the majority of the developing countries remaining only in the
poorest regions of the less developed world, where the access to safe water
and adequate health care system is lacking (Molyneux et al., 2005). To date,
these NTDs place a substantial burden in those regions, increasing both the
marginality and poverty of the population and cost developing economies
billions of dollars every year. In addition, a remarkable growth of the po-
pulation will take part in the less developed countries increasing, therefore,
the spread of these infection diseases (Hotez, 2013).
NTDs reduce the physical and cognitive development of people and
limit their opportunities for life and productivity at work, becoming a
dangerous circle of poverty and disease. Even though NTDs produce mas-
sive but hidden and silent suffering, people most at risk do not have easy
access to an effective treatment or prevention (Keenan et al., 2013).
In general, NTDs occur between individuals and families with a
deficiency of proper sanitation and safe drinking water, inadequate
housing, and crowded living conditions. These pathologies occur in
communities living in areas of conflict, also (Hotez, 2017).
Most of them are very old and well-known diseases that have been
affected larger populations for centuries. The scientific literature de-
scribes seventeen NTDs, many of them are chronic that may become
progressively worse without treatment, however, the World Health
Organization (WHO) recently added three other infectious disease to
the commonly known classification (WHO, 2017).
Regardless the geographical regions, the consequences of NTDs are
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highly costly for societies and healthcare. The costs include intensive
care required by patients of dengue hemorrhagic fever and rabies,
surgical procedures and longer hospital stays in cases of Buruli ulcer,
and rehabilitation required of those suffering from leprosy and lym-
phatic filariasis (Marchal et al., 2011).
Some of the NTDs are transmitted by vectors (vector-borne diseases)
that can transmit infectious diseases between humans or from animals
to humans. Commonly, the vectors are often found in tropical regions,
where insects prevail, and access to drinking water and sanitation is not
safe (Valenzuela and Aksoy, 2018). Many of them are bloodsucking
insects, which ingest disease-producing microorganisms during a blood
meal from an infected host (human or animal) and later inject it into a
new host during their subsequent blood meal. These vector-borne dis-
eases are disorders caused by pathogens, including parasites, in hu-
mans. Mosquitoes are the best-known vectors of diseases. Tick, flies,
sand flies, fleas, triatomines and some freshwater snails are also vectors
of several diseases (Fournet et al., 2018). To date, the world register
every year more than 1 million deaths as a result of diseases transmitted
by vectors (Eder et al., 2018), such as dengue, schistosomiasis, human
African trypanosomiasis, leishmaniasis, Chagas disease, yellow fever,
Japanese encephalitis and onchocerciasis. According to the literature,
vector-borne diseases represent nearly 17% of the global burden of
infectious diseases. Social, demographic and environmental factors are
crucial for the spread of vector-borne pathogens (Eder et al., 2018).
In the American continent, Chagas disease is a major NTD caused by
infection with the protozoa, Trypanosoma cruzi (T. cruzi), transmitted,
mainly, by the “kissing bugs” insects, through the bite wound or mu-
cous membranes (Pérez-Molina and Molina, 2018). It is the most im-
portant public health issue and one of the leading causes of morbidity,
long-term disability and mortality in such geographical region, with
estimates of nearly 80 million people at risk of infection, and more than
10 million infected in 21 endemic countries (Ventura-Garcia et al.,
2013).
2. Chagas disease
Chagas disease, also known as American trypanosomiasis, it was
discovered by the Brazilian Carlos Chagas, who investigated the infec-
tion produced by the protozoan T. cruzi, more than a century ago. He
was able to describe the entire life cycle of T. cruzi as well as the cor-
responding vectors and the final hosts (animals and human)
(Aufderheide et al., 2004). It has been reported that, annually, the
global burden of Chagas disease is around $627 million in terms of
health costs and more than 800,000 disability-adjusted life-years
(DALYs) (Lee et al., 2013).
In regions where Chagas disease is endemic, the main form of
transmission is through vectors (triatomines). These blood sucking in-
sects are infected after biting an infected animal or human. Once they
bite and ingest the blood of a new host, they defecate close to the bite.
The host may become infected if parasites of T. cruzi present in insect
feces get into the body through mucous membranes or cuts on the skin
or when the person rubs the area of the bite in an instinctive reaction
(Yamagata and Nakagawa, 2006). Additionally to vector transmission,
there are other routes of Chagas disease transmission including blood
transfusions, organ transplants, transmission from mother to child
during pregnancy and the intake of contaminated food (Angheben
et al., 2015). It is not transmitted by direct contact with infected people
(WHO, 2010; Howard et al., 2014). Lately, a remarkable advance in the
control of both the vector and blood supply sources for T. cruzi infection
has been noticed in many countries, by means of governmental control
programmes (Antinori et al., 2017).
It is worth of mentioning that every year more than 15,000 babies
are born infected by T. cruzi, worldwide. However, less than 20%, will
be early diagnosed and treated. According to the experts, the congenital
transmission (mother to child) is the route that produces greater
number of new acute cases and, therefore, such way of transmission is
the key to controlling the disease, both in endemic and non-endemic
regions (Costales et al., 2015).
In this regard, more than 1 million women in fertile age are infected
with T. cruzi, which poses a high risk of new infections due to an in-
fected woman may transmit the parasite to the child during pregnancy
or childbirth (it is calculated a risk between 3% and 5%) (Dumonteil
et al., 2019).
Parasiticidal treatment has success rates in acute and congenital
disease, reactivations and indeterminate chronic phase in young pa-
tients (< 18 years) (Reithinger et al., 2009). However, its efficacy in the
chronic stage in adults is still subject of intense controversy though it
has increased in the past decade due to recommendations to reduce
cardiac symptoms (Garcia et al., 2005). According to a study conducted
in different health centers of Argentina the risk of the occurrence of
congenital transmission in treated mothers was 25 times lower than
those untreated before pregnancy (Fabbro et al., 2014).
3. Chagas disease chemotherapy
According previous reports, the discovery of new chemical entities
(NEC) for the treatment of global diseases including cancer, Parkinson
disease and other neurodegenerative pathologies, diabetes and cardio-
vascular disorders has been remarkable increased in the last decades in
both the academy and pharmaceutical industry (Dixon et al., 2010).
However, a complete opposite situation has occurred in the case of the
NTDs, mainly due to the lack of economic interest by the pharmaceu-
tical companies and the almost complete absence of economic support
to the academic research groups (Hotez et al., 2009). Thus, even though
few medicines were discovered, lately, for the treatment of some NTDs,
unfortunately, none of them was for the treatment of Chagas’ disease
(Rassi et al., 2010; Weng et al., 2018). On the other hand, although a
remarkable advance in the study of T. cruzi genome was achieved, a
vaccine is still lacking for the successful treatment of Chagas disease
(Villanueva-Lizama et al., 2018).
Unfortunately, the investment needed to develop a new medicine is
a critical step due to nearly US $1400 million is the cost for approving a
new biological active molecule (DiMasi et al., 2016). In the particular
case of NTDs, including Chagas disease, the lack of interest showed by
the pharmaceutical companies is due to, mainly, the majority of the
infected population lives in rural and poor urban areas. Thus, it is al-
most impossible for them to afford the costs of the novel medicines
confirming that such economic market is not attractive, in terms of
business, for the corresponding companies (Frew et al., 2009).
To date, there are only two approved drugs for the treatment of
Chagas disease: benznidazole (BNZ) and nifurtimox (NFX) (Fig. 1). Both
of them discovered more than 45 years ago, are included in the WHO
Fig. 1. Nifurtimox and Benznidazole. Unique treatment
available for Chagas disease.
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Model List of Essential Medicines (WHO, 2015)
Unfortunately, these medicines are not always available in many
regions of Latin America (Salomon, 2012). Even though The London
Declaration on Neglected Tropical Diseases announced the elimination
or control of ten neglected diseases, including Chagas disease, by 2020,
current estimations indicate that less than 1% of infected population
with Chagas is treated (Bartsch ert al., 2018).
BNZ [2-Nitro-N-(phenylmethyl)-1H-imidazole-1-acetamide] is the
antichagasic drug of choice due to its biological effects and acceptable
biopharmaceutical performance. The recommended dose for adults is
5–7mg/kg orally while the corresponding dose for children up to 12
years old is 5–10mg/kg orally, both in two divided doses administered
daily for 30–60 days (Viotti et al., 2009). It was launched in 1971 by
Roche and available as Rochagan® in Brazil and Radanil® in Argentina.
In 2003, the license and rights of benznidazole were transferred to a
Brazilian public pharmaceutical laboratory of the Pernambuco State
(LAFEPE) (Alpern et al., 2017). Then, Drugs for Neglected Diseases
Initiative (DNDi) and LAFEPE formulated a pediatric formulation for
children weighing< 20 kg (12.5mg BNZ per tablet). Registered in
Brazil (Brazilian Health Surveillance Agency, 106 ANVISA), in 2013
was added to the WHO Model List of Essential Medicines for Children
(Seremeta et al., 2019; Sales Junior et al., 2017). On the other hand, a
public and private Argentinean consortium constituted by the Ministry
of Health, Maprimed and Elea, both pharmaceutical companies, and
Mundo Sano Foundation, started in 2012 the synthesis and production
of generic version of BNZ and the development of the respective 100, 50
and 12.5mg scored tablets. Currently, this consortium is the unique
source of BNZ worldwide. In 2017, the U.S. Food and Drug Adminis-
tration (FDA) approved BNZ for the treatment of children (2–12 years
old) with Chagas disease, being the first drug registered by the in-
stitution for the treatment of Chagas disease (FDA, 2017).
NFX [5-nitrofuran (3-methyl-4-(5′nitrofurfurylideneamine) tetra-
hydro-4H-1,4-tiazine-1,1-dioxide)] it was registered and manufactured
by Bayer Health Care (Lampit®). Since 1967, it is commercially avail-
able as tablets prescribed at dosages of 8–10mg/kg/day for 90–120
days (Chirac and Torreele, 2006). Even though NFX is prescribed in all
the phases of the disease, the higher efficacy of NFX is during the acute
phase of the infection in children and patients recently infected
(Rodriques Coura and de Castro, 2002). NFX production was dis-
continued in 1997 and it was restarted in 2000 after the requirements of
WHO for the treatment of both the African trypanosomiasis and Chagas
disease (Jannin and Villa, 2007; Shegokar, 2013). In 2013, a clinical
trial (phase I) with infected chronic patients was carried out to analyze
the biopharmaceutical properties of a new 30mg tablets of NFX com-
pared with the commercially available 120mg tablets. The results
showed that both solid dosage forms were bioequivalents, suggesting
the efficacy of NFX at low doses (Sales Junior et al., 2017). The me-
chanisms of action of these trypanocidal agents are still under analysis,
suggesting that BNZ reduction leads to the formation of glyoxal, a cy-
totoxic compound (Hall and Wilkinson, 2012). In the case of NFX, its
metabolization produces nitrile derivative, which exhibit the anti-
parasitic activity (Hall et al., 2011). Unfortunately, in the last years,
several reports described some kind of resistance of T. cruzi to both BNZ
and NFX (Filardi and Brener, 1987; Veloso et al., 2001; Wilkinson and
Kelly, 2009)
Although both drugs are widely used, one of its major disadvantages
is the appearance of serious adverse effects. In the case of NFX, the
patients may suffer different adverse effects including psychiatric and
neurological disorders and gastrointestinal complications (Jackson
et al., 2010). On the other hand, patients under treatment with BNZ
may present cutaneous eruption, generalized edema, fever, poly-
neuropathy, polyneuritis and bone marrow complications (Bern, 2011).
4. Nanotechnology approaches for chagas disease
In general, the majority of the drugs used for the chemotherapy of
NTDs, are poorly soluble in water. In the case of BNZ, experimental data
obtained by Maximiano et al. (2010) showed that the solubility of BNZ
in distilled water or simulated gastric and enteric fluids is approxi-
mately 0.2 mg/ml. However, other reports informed that BNZ solubility
value is 0.4mg/ml (Kassim et al., 2004; Figueirêdo et al., 2018). In
addition, determination of partition coefficient indicated that the Log P
value was approximately 0.7. According to the Biopharmaceutical
Classification System (BCS), BNZ belongs to Class IV drug (reduced
solubility and permeability) (Kassim et al., 2004; Maximiano et al.,
2010). However, it should be mention that BNZ is also included in the
Class II of the BCS, which indicate a reduced drug solubility and high
permeability (Lima et al., 2011; Ferraz et al., 2018). Moreover, The
International Pharmacopeia (WHO, 2018) describes BNZ as practically
insoluble in water. In accordance with all those evidences, a low and
erratic bioavailability is usually expected. Due to aqueous solubility and
drug dissolution rate are critical parameters to control the rate of ab-
sorption and further bioavailability, the presence of polymorphs can
greatly modify the corresponding drug solubility and, then, its bio-
pharmaceutical properties (Censi and Di Martino, 2015). Thus,
Maximiano et al. (2011), decided to evaluate whether BNZ would ex-
hibit polymorphism after the recrystallization from mixtures of dif-
ferent solvents. By thermal analysis, the authors confirmed the ap-
pearance of, at least, on polymorph of BNZ. Later, Honorato et al.
(2014) identified by X-ray powder diffraction three different powder
patterns corresponding to three different polymorphs of BNZ (Forms I,
II and III). Solubility assay showed that the solubility in water of such
structures were 0.22mg/ml (Form I), 0.24mg/ml (Form II) and
0.25mg/ml (Form III). These findings were in accordance with the
work of Maximiano et al. (2010). This information possess direct im-
plications on the BNZ stability and aqueous solubility leading, then, to
the formulation of the most convenient dosage form.
NFX is classified into the class III of BCS (Kasim et al., 2004) sug-
gesting a high-solubility and low-permeability properties. However, in
agreement with the International Pharmacopeia, it is considered prac-
tically insoluble in water (WHO, 2018). Unfortunately, data related
with polymorphism, solid-state properties and drug stability are not yet
available in the literature.
Concerning the BNZ and NFX physicochemical properties, the na-
notechnology offers some innovative strategies based on the reduction
of the particle size to nanometric scale, to overcome both solubility and
permeability issues. In such scale, at least one dimension must be in the
range of 10–1000 nm (1 nm=10−9 m) in order to make use of size and
structure dependent properties and phenomena, which vary at this re-
duced size because of the limited electrons movement, increase of su-
perficial area, aggregation, among others (Desai, 2012). Taking into
account, this novel technology can have a significant impact to improve
several biopharmaceutical characteristics of lipophilic drugs including
aqueous solubility, dissolution rate, biodistribution, stability during
host-circulation, bioavailability, uptake mechanisms, specificity, effi-
cacy, and sustained release (Pathak and Thassu, 2016). The design of
nano-drug delivery systems includes liposomes, nanoemulsions, nano-
crystals, polymeric, lipid and metallic nanoparticles. Such nanosystems
are able to transport drugs to the intracellular target, reducing toxic
effects due to its specificity and drug concentration achieved inside the
target (Al-Kassas et al., 2017). Over the last decades, different techni-
ques to produce nanomedicines were study to enhance the bio-
pharmaceutical characteristics of several drugs for the treatment of
NTDs (Islan et al., 2017).
Additionally, and in agreement with several studies, nanomedicines
may successfully to overcome the resistance to multiple antimicrobial
agents (AlMatar et al., 2017; Baptista et al., 2018). Then, it could be
possible to postulate herein that similar nanocarriers might be able to
avoid the mechanisms of resistance to BNZ, NFX and other ni-
troheterocyclic drugs including the mutation of a nitroreductase and
the P-glycoprotein efflux pump (Guedes et al., 2004). Following similar
mechanistic pathway than other nanoformulated systems, BNZ or NFX
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nanostructures might cross the cell membrane by specific mechanisms
and release the drugs at the target site in a more efficient manner than
the untreated drugs, potentially avoiding the drug-resistance (Murta
et al., 1998; Garcia-Salcedo et al., 2016). However, to the best of our
knowledge, research studies are still lacking, so far, to confirm the
suitability of nanoformulated BNZ or NFX to reduce such resistance.
Considering this scenario, the development of a suitable pharma-
ceutical systems to improve the physicochemical properties (solubility,
dissolution rate and stability) as well as the biopharmaceutical perfor-
mance of both BNZ and NFX to achieve a more effective therapy with
reduced adverse effects is highly necessary (Figueirêdo et al., 2018;
Santos Souza et al., 2017; Ferraz et al., 2018).
5. Nifurtimox nanoparticles
In agreement with the literature, the advantages of the design of
polymeric nanosystems for drug delivery are, mainly related with the
capacity of targeting specific cell, tissues and organs (Choi and Han,
2018). Depending on the type of polymer selected, such nanostructures
may be able to modulate the release of the encapsulated drug as well as
to modify nanoparticle surface and circulation time. However, in some
cases, intermediate byproducts can be formed through biodegradation
process increasing the toxicity of those nanocarriers (Nicolas et al.,
2013). In agreement with it, a deep knowledge about the mechanisms
of drug uptake, cellular trafficking and distribution as well as binding to
specific receptors is required. In this regard, González-Martin et al.
(1998) published the formulation of NFX polyalkylcyanoacrylate na-
noparticles as targeted delivery systems for the treatment of Chagas
disease. Ethylcyanoacrylate nanocarriers were formulated by means of
emulsion polymerization process. Different concentrations of NFX,
polymers and nonionic Tween® 20, as surfactant agent, were assayed to
prepare such nanosystems. NFX nanoparticles with a particle size less
than 200 nm, as measured by scanning electron microscopy and cyto-
metry, were obtained. The NFX encapsulation efficiency was nearly
34%, however, it was decreased as the amount of drug was increased.
Analysis of drug release patterns indicated that, at pH 1.2 and pH 7.4,
20% and 65% of NFX was released from nanoparticles, respectively.
This finding could be related with the erosion surface of the polyalk-
ylcyanoacrylate carrier by increasing the pH, as described in 1995 by
Cicek et al. In-vitro studies using cultures of T. cruzi epimastigotes,
isolated from a chronic chagasic patient, indicated an enhanced anti-
parasitic efficacy compared to a standard solution of raw NFX. Thus, the
parasitism rate was, markedly reduced up to 94% after 2 h incubation
with 0.001% of the NFX nanoparticle suspension. Microscopy evalua-
tion displayed intracellular damage, degeneration of the kinetoplast,
and lysis of membrane of the parasite. In addition, similar cellular al-
terations were observed in treated isolated amastigotes. A non-expected
trypanocidal activity was found when parasites were treated with un-
loaded nanoparticles. Even though no mechanism was described to
elucidate such finding, it could be postulated that a potential de-
gradation of polyalkylcyanoacrylate may produce formaldehyde, which
is toxic for the parasites. Later, Sánchez et al. (2002) reported both the
formulation of polyethylcyanoacrylates nanoparticles loaded with NFX
and in-vitro trypanocidal activity on cell-culture-derived trypomasti-
gotes and on intracellular amastigotes. NFX nanosystems were prepared
by means of an emulsion polymerization process with ethylcyanoa-
crylate and Tween® 20 in dimethylsulfoxide. The characterization of
the nanoformulations showed particles with average size of 200 nm and
an encapsulation capacity of 8.2 μg of NFX per milligram of nano-
particles. In-vitro trypanocidal studies on free trypomastigote forms
were performed using eight different concentrations of both NFX en-
capsulated and non-encapsulated. A 100% trypanocidal effect was ob-
tained when NFX nanoparticles were used at a concentration of 1.85 μg
ml−1. To reach a similar trypanocidal activity, non-encapsulated NFX
was used at a concentration of 5.55 μg ml−1. In particular, at low
concentration of NFX (0.21 μg ml−1), the corresponding trypanocidal
activity of loaded nanoparticles and free drug were 83.1% and 53.9%,
respectively. The IC50 of NFX nanoparticles was 0.17 μg ml−1 whereas
the IC50 of free NFX was remarkable lower (0.008 μg ml−1) and cyto-
toxicity studies on Vero cell line confirmed that both NFX loaded and
non-loaded formulations presented a cytotoxic effect. On the other
hand, comparison of the trypanocidal activity on trypamastigote forms
between the NFX nanoparticles and the respective solution indicated
that at lower concentrations (0.21 and 0.62 μg ml−1), nanoparticles
were more active than the drug in solution. In agreement with the re-
sults of both publications, NFX nanoparticles exhibit in-vitro trypano-
cidal activity on both free trypomastigotes and intracellular amasti-
gotes, by means of degeneration and lysis processes of the membrane of
T. cruzi. However, more studies are required to improve the en-
capsulation efficacy and confirm the detectable toxic effects of the
polymeric carrier. According the literature survey, no further studies
are available, to date, related with the formulation and in-vivo evalua-
tion alternative NFX nanosystems.
6. Benznidazole nanocrystals
Nanocrystals, in a form of nanosuspensions, are a very attractive
approach for administration of poorly-water soluble drugs through
various routes, such as oral, parenteral, ophthalmic, transdermal and
pulmonary delivery. These nanoformulations improve both physico-
chemical and biopharmaceutical properties of the drugs including so-
lubility, dissolution rate, absorption, bioavailability, potential site-
special drug delivery, and suitability for drugs with a narrow absorption
window (Müller et al., 2001). Nanocrystals of lipophilic drugs are ob-
tained through well-known methodologies named: (1) the bottom-up
process (nanoprecipitation) and (2) the top-down process (milling). The
bottom-up or down-up technique belongs to the molecular nano-
technology. It focuses on the construction of structures and objects from
their atomic and molecular components (Merisko-Liversidge et al.,
2003). Particularly, the main goal of the 'bottom up' technology is to
join small structures to make larger structures. This process starts with
the molecules in solution and its further aggregation to form the solid
particles. Nucleation and crystal growth are the two main steps for
nanocrystal formation. Precipitation or recrystallization may be pro-
duced through different technologies including liquid solvent-anti-
solvent addition, supercritical fluid, solvent elimination and high-en-
ergy processes (Sinha et al., 2013). However, it is necessary to mention
that this alternative also may exhibit a low stability of drugs due to the
absence of a protective carrier material (polymer, lipid). Regarding
Chagas disease, a solvent-antisolvent precipitation (bottom-up tech-
nique), for preparing BNZ nanosuspensions was reported by Scalise
et al. (2016) for the first time. Nanocrystals were formulated through
the nanoprecipitation technique using as stabilizer poloxamer 188, a
nonionic copolymer with a central hydrophobic chain of poly(propy-
lene oxide) and two hydrophilic chains of poly(ethylene oxide), with an
average molecular weight of 8400 Daltons. BNZ was dissolved in
ethanol (solvent), and added dropwise to a water/poloxamer 188 so-
lution (antisolvent). Due to the nanoprecipitation process is a phe-
nomenon of high surface energy, the particles may form aggregates or
agglomerates and, therefore, is it necessary to add one or more stabi-
lizers. In this work, poloxamer 188 stabilized the BNZ nanocrystals by
means of steric hindrance avoiding the respective particle aggregation
and growth. The average particle size of the BNZ nanocrystals was in a
range of 60–65 nm with a size distribution (PDI) of 3.35 ± 0.1 and a ζ-
potential value of -18.30 ± 1.0. In agreement with those results, the
nanoprecipitation process was a very promising approach to formulate
BNZ in nanoparticles. Once characterized, nano-BNZ was evaluated in-
vitro for cytotoxicity using a Vero cell cultures. The results of the MTT
assay indicated slightly differences between the cultures treated with
10, 25 and 50 μg/ml of BNZ nanocrystals suspended in PBS and un-
treated drug. Moreover, no morphological modifications of the cell
membrane were microscopically observed suggesting the safety of such
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nanoformulations in terms of cell viability. Then, blood compatibility
was examined to analyze the potential application of nanoformulated
BNZ as chemotherapeutic agent. In contrast to other nanosystems that
produce lysis of the red blood cells, this assay demonstrated no he-
molysis of the red blood cells after incubation with both BNZ nano-
particles and raw BNZ. Having on mind that the parasite infects the
heart tissues, the effects of BNZ nanocrystals were evaluated in infected
myocytes. The results showed a remarkable inhibition of amastigote
growth in cardiac cells using low concentrations of drug. It could sug-
gest that nanoformulated BNZ may penetrate the heart tissues and in-
crease its activity against the intracellular growth of T. cruzi amasti-
gotes. To evaluate the trypanocidal activity of nanoformulated BNZ, an
assay in the acute phase T. cruzi infected mice was carried out. Thus, a
100% survival for at least 50 days was observed after treatment during
30 days with BNZ nanosystems (50, 25 and 10mg/kg/day). Then, the
trypanocidal in-vivo assay was performed during 15 days and the results
indicated a 100% survival (50 days) for infected mice treated with 50
and 25mg/kg/day, suggesting that this nanosystem presents in-vivo
trypanocidal activity in dose dependent manner. Later, the same re-
search group evaluated the efficacy of nanoformulated BNZ, in different
concentrations, administered during the acute phase in infected mice
that were immunosuppressed during the chronic phase. Production of
T. cruzi-specific antibodies, heart cells inflammation and ROS produc-
tion by Vero cells, were also evaluated. In-vivo assay showed a reduc-
tion in T. cruzi-specific antibodies in comparison with those of the un-
treated infected mice, after treatment with nanoformulated BNZ
(25mg/kg/day). No antibodies were found in 50% of mice after 90
days and 100% after 180 days. However, treatment with 50mg/kg/day
showed the absence of antibodies after 90 days. In contrast, both mice
treated with raw BNZ and untreated mice displayed no differences in
antibody titer. In addition, heart tissue inflammation produced by the
parasite was diminished after treatment with nano-BNZ (25 and 50mg/
kg/day) (Rial et al., 2017). According these results, BNZ nanocrystals
would be able to reach intracellular parasites, probably due to the
improved solubility and permeation of the drug when nanoformulated.
However, more research is required to develop a stable and secure
nano-BNZ, taking into account that this new strategy may result in a
novel chemotherapeutic treatment for Chagas disease.
7. Benznidazole nanoparticles
The polymeric encapsulation of the non-polar BNZ at the nanometer
scale changes its specific surface properties. This could improve the
ability to cross biological barriers and targeting the affected tissues
(Silva-dos Santos et al., 2017). Thus, Seremeta et al. (2019) described
the nanoencapsulation of BNZ using Eudragit® by nanoprecipitation
and freeze-drying process using a single polymer (Eudragit® RL PO or
Eudragit® RS PO) or a blend (Eudragit® RL PO/Eudragit® RS PO, 1:1 wt
ratio). The production yield after the process was nearly 86% and the
encapsulation efficiency was around 95%. The freeze-drying process
did not greatly modify the particle size. The range of the hydrodynamic
diameter, before and after freeze-drying, was between 201–250 nm and
242–303 nm, respectively, with polydispersity index value below 0.2
indicating size homogeneity. Freeze-dried nanoparticles storage at
4 ± 2 °C and then dispersed in water exhibited a stable behavior. After
70 days, the particle size was varied between 270–321 nm. In-vitro re-
lease studies in medium of pH 1.2 at 37 °C showed enhanced BNZ
dissolution rate from nanoparticles with respect to raw drug due pos-
sibly to a reduction of the both size and drug crystallinity after process.
Values of drug dissolution efficiency at 30min (DE30), 60 min (DE60)
and 120min (DE120) for BNZ-loaded nanoparticles were 20.5, 36.9 and
63.9, respectively. While in the case of the untreated drug these values
were 5.5, 12.3 and 27.2 respectively. This indicates a statistically sig-
nificant increase of ED with respect to free BNZ (p < 0.001).
On the other hand, Nhavene et al. (2018) designed a nanosystem
comprising mesoporous silica nanoparticles (MSNs) with chitosan-
succinate covalently attached to their surface pore to act as anchor for
BNZ. Chitosan is a versatile biomaterial produced by the alkaline dea-
cetylation of natural chitin. It is a biocompatible and biodegradable
polymer and possess low immunogenicity characteristics, while MSNs
are solid inorganic compounds with specific physicochemical properties
due to it is possible to control its pore and particle size. Thus, the
combination of chitosan with MSNs, using trimethoxysilane as covalent
crosslinker, might help to formulate a novel carrier with particular
properties that may facilitate the cellular uptake. Thus, the transmission
electron microscopy characterization of these nanocarriers showed the
presence of spherical nanoparticles with highly ordered mesoporous
structures and hexagonal arrays of uniform pores. Then, the ζ-potential
analysis gave as a result a negative value, probably related to the silanol
groups of the silica, in agreement with other reports. However, by
adding chitosan to the nanocarrier, the ζ-potential changed to a positive
value, probably due to the positively charged amino group of chitosan.
In any case, this modification confirmed the functionalization of the
silica. By solid-state nuclear magnetic resonance was also possible to
confirm the functionalization of the MSNs with chitosan succinate and,
then, the drug loading on the surface of the MSNs. In particular, the
reaction of chitosan to mesoporous silicate using the crosslinking agent
is through a nucleophilic attack of the amino groups of chitosan to the
less steric carbon of the epoxide. After the covalent attachment of
chitosan to the mesoporous carbon chain, new signal peaks related with
specific carbon atoms of the main chain were detected. Finally, cou-
pling of BNZ to the silicate-chitosan structure was also confirmed by
solid-state nuclear magnetic resonance. In-vitro assay using epimasti-
gotes of T. cruzi CL Brener strain indicated that the free-BNZ carriers
were not toxic against parasites and a normal grow of the strain was
detected. In contrast, nanoformulated BNZ are cytotoxic and inhibit the
growth of the epimastigote forms. Thus, a remarkable decrease of the
rate of live parasites in presence of encapsulated BNZ was observed
when compared to untreated BNZ. The findings of this research in-
dicated that nanoformulated BNZ at low concentration exhibit a similar
inhibitory antiparasitic effect than high concentrations of drug sug-
gesting that this “nano” approach is a very useful tool to reduce the
infection. In another work, Tessarolo et al. (2017) described the pre-
paration of CaCO3 nanoparticles for the delivery of BNZ. The nano-
particles were obtained by mixing a solution of BNZ in ethanol:water,
with calcium chloride, sodium carbonate and sodium citrate solutions
using two surfactants: sodium dodecyl sulphate and poloxamer 188.
The analysis by atomic force microscopy indicated that particle size of
spherical empty CaCo3 nanoparticles were within the size range of
27–64 nm. The loading amount of BNZ in CaCo3 nanoparticles was
determined by infrared absorption spectroscopy and after the corre-
sponding interpolation of the drug absorbance in different diluted so-
lutions the concentration of encapsulated BNZ was around 25%. In-
cubation of BNZ nanoparticles with epimastigote forms showed a
growth inhibition at 24, 48 and 72 h, in dose-dependent manner. At
24 h, IC50 of encapsulated BNZ and untreated BNZ were 8.72 μgmL−1
and 56.7 μgmL−1, respectively, while at 72 h, IC50 values were
4.8 μgmL−1 and 4.3 μgmL−1, respectively. The inhibition effects of
nanoformulted BNZ were more pronounced in the first 24 h of the
assay, probably due to a fast drug release from the CaCo3 nanocarrier.
The evaluation of the viability of trypomastigotes showed that en-
capsulated BNZ was more effective than the untreated drug in all as-
sayed concentrations. Thus, at 24 h, the LC50 of BNZ nanoparticles was
1.77 ± 0.58 μg mL−1, while the LC50 of raw drug was 66.9 ± 20.3 μg
mL−1. Finally, the in-vitro assay against amastigote forms, demon-
strated that BNZ nanoparticles exhibited a similar antiparasitic effect
than the untreated BNZ, confirming that BNZ loaded in CaCo3 nano-
particles is a suitable approach against the epimastigote forms as well as
against both blood trypomastigotes and intracellular amastigotes
(Tessarolo et al., 2017).
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8. Benznidazole lipid nanovesicles
Lipid nanovesicles represent one of the most interesting supramo-
lecular assemblies due to several reasons including convenient size,
surface properties, high drug-loading capacity, chemical modification
of the surface, biocompatibility and biodegradability (Romero and
Morilla, 2013). In particular, liposomes are amphiphilic, biodegradable
and biocompatible spherical vesicular structures constituted by, at
least, one lipid bilayer formed by the dispersion of phospholipids and
other lipid derivatives into water (Sercombe et al., 2015). These lipid
vesicles display an excellent capacity to carry hydrophilic or lipophilic
molecules as well as an improvement of the therapeutic efficacy of the
encapsulated drug. Moreover, liposomes are very useful for targeting
specific cellular targets (Allen and Cullis, 2013). However, these lipid
nanosystems exhibit some disadvantages including fast elimination
from the bloodstream, short half-life, oxidation and hydrolysis de-
pending the lipid composition, and high production costs (Akbarzadeh
et al., 2013). Then, its development should be evaluated in any parti-
cular case.
Morilla et al. (2002) prepared liposomes with the aim to increase
BNZ permeability, reduce its degradation in liver and intestines and,
finally, to reach specifically infected cells. Nanocarriers were prepared
using soybean:cholesterol:distearoyl-phosphatidylglycerol (molar ratio
2:2:1, mol/mol/mol) and BNZ dissolved in dimethyl sulfoxide. Drug
loading obtained was of 2 g BNZ/100 g total lipids at a total lipid
concentration of 20–30mM. Release of drug upon dilution assays (450-
folds) in 10mM buffer Tris−HCl (pH 7.4) at 37 °C showed a fast drug
lost at the beginning (65% drug lost/min), followed by a second step
where stopped leaking (0.4% drug lost/min) (Morilla et al., 2002). In
2004, the researchers performed an in-vivo assay treating non-infected
rats, by intramuscular, subcutaneous, and intravenous routes to eval-
uate whether the new nano-BNZ would improve the biopharmaceutical
properties of the drug including biodistribution and bioavailability. In
the case of intravenous route, after a dose of 0.2mg drug/kg, a major
amount of BNZ liposomes was detected in liver compared to the free
drug. Even though it could be a promising result, after the repeated
intravenous administration of liposomal BNZ (0.4mg/kg, twice a week
from day 5 to day 22, post-injection), it was not observed a reduction of
the parasitemia in infected mice. In agreement with the authors, after
the phagocytosis process, the intracellular pathway of the encapsulated
BNZ and its further release could be due to the permeation capacity of
the drug across the membrane. The chemical constitution of the lipo-
somes might also improve the BNZ delivery to the site of action (Morilla
et al., 2004).
Recently, Vinuesa et al. (2017) described the in-vitro trypanocidal
effect and cell viability of both BNZ liposomes and quatsomes, non-
liposomal vesicles constituted by quaternary ammonium surfactants
and cholesterol. Liposomes were formulated following the traditional
technique using three different mixtures of cholesterol and dipalmi-
toylphosphatidylcholine, and quatsomes were prepared using mixtures
of cholesterol-benzalkonium chloride or cholesterol-myristalkonium
chloride. The procedure was carried out using compressed CO2. BNZ
and the lipid components of the carriers were dissolved in ethanol and
the resulting solution was poured into a high-pressure autoclave and
pressurizing it with compressed CO2. The homogeneous cholesterol-
based nanostructures were obtained after depressurizing the resulting
CO2-expanded solution in an aqueous phase. Unloaded quatsomes were
within the size range of 46–124 nm, depending their composition while
unloaded liposomes appeared in a size range of 103–117 nm. On the
other hand, liposomes loaded with BNZ (0.3%) exhibited a size of
118 ± 26 nm and a ζ-potential of −9.7 ± 0.8mV. In-vitro evaluation
of the cell viability indicated that all unloaded quatsomes were toxic,
being unsuitable as BNZ carriers. On the other hand, unloaded lipo-
somes display a very low toxicity in contrast to the BNZ loaded lipo-
somes, which displayed toxic effects even at low concentration. In-vitro
trypanocidal activity of the unique BNZ loaded nanovesicle showed a
very low biological effect, probably due to the low concentration of
drug in the liposomes. Therefore, although these studies are a valuable
approach for improving the BNZ delivery, further studies are required
to formulate BNZ liposomes with an effective biological activity against
T. cruzi infection (Vinuesa et al., 2017).
9. Benznidazole solid lipid nanostructures
One the most widely explored approaches to formulate particles of
sub-micron dimensions loaded with both hydrophobic and hydrophilic
drugs are the solid lipid nanoparticles (SLNs) and nanostructured lipid
carriers (NLCs) (Almeida and Souto, 2007; Shidhaye et al., 2008). These
colloidal nanocarriers, constituted by a mixture of one or more lipids
and a water-surfactant solution exhibit several advantages including
small size, composition, drug controlled release, biocompatibility and
biodegradability (Huynh et al., 2009). It is worth mentioning that lipid
nanostructures are attractive pharmaceutical alternative to polymeric
nanoparticles in terms of stability, toxicity and manufacturing issues
and drug release. These lipid-based nanosystems are prepared by dif-
ferent methodologies including solvent emulsification/evaporation,
melt homogenization, ultrasonication/high speed homogenization, su-
percritical fluid and spray-drying (Mishra et al., 2018). However, de-
pending the selected methodology it is necessary to consider the ne-
gative impact of the residual organic solvents used to formulate such
lipid nanostructures. Other disadvantages are the low drug loading ef-
ficiency and an initial fast release. Additionally, it the samples are
prepared using the high-pressure homogenization technique, it is pos-
sible to observe drug degradation by the high temperature applied.
Furthermore, it is common to observe certain drug expulsion due to the
recrystallization during storage (Ghasemiyeh and Mohammadi-Samani,
2018).
Vinuesa et al. (2017) formulated SLNs and NLCs for the delivery of
BNZ by emulsion solvent evaporation and melt homogenization, re-
spectively, followed by freeze-drying using trehalose (15%) as cryo-
protectant. The physicochemical characterization of the nanoformula-
tions showed that BNZ loaded SLNs exhibited an average size of
166 nm, before lyophilization, and a ζ-potential of −21mV. The en-
capsulation efficiency was between 83 and 95%, depending the drug
loading. The analysis of the loaded NLCs showed particles with an
average diameter of 202 nm and a ζ-potential of −26mV. The en-
capsulation efficiency was almost quantitative (98–99%). In-vitro stu-
dies using epimastigote forms (CL strain) indicated a major trypano-
cidal activity displayed by raw BNZ compared to loaded SLNs and
loaded NLCs. This finding would be due to the low and incomplete
release of BNZ from the nanocarriers. According to these results, further
studies are needed to improve both the drug loading and the corre-
sponding release rate in order to potentially reduce the growth of T.
cruzi in a more effective manner (Vinuesa et al., 2017).
10. Benznidazole cyclodextrin nanometric complexes
Cyclodextrins (CDs) are cyclic oligosaccharides (cycloamyloses) that
comprise (α-1-4)-linked α-D-glucopyranose units. They are doughnut-
shaped molecules or bucket-like or truncated cone with hydrophilic
outer surface and a hydrophobic central cavity. Thus, CDs can form
non-covalently bonded inclusion complexes (host–guest complexes)
with a wide variety of compounds increasing the aqueous solubility and
physicochemical stability of the guest molecule. Therefore, CDs are
widely used in the pharmaceutical industry to improve solubility and
oral bioavailability while diminishing toxicity (Lakkakula and Krause,
2014). It is possible, also, to control drug release from stable complexes
and increase drug permeability through biological barriers (Conceição
et al., 2018).
Regarding Chagas disease, Lyra et al. (2012) obtained and char-
acterized inclusion complexes of BNZ and β-CD or randomly 2-me-
thyled-β-cyclodextrin (RM-β-CD) in aqueous solution. Results of phase-
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solubility diagram showed that BNZ solubility increases linearly with
CD concentration and linear regression analysis suggested the forma-
tion of complexes with 1:1 stoichiometry. Phase-solubility diagrams in
water at 25 °C showed that RM-β-CD formed complexes were more
stable than the natural CD (β-CD) with enhanced complexation and
solubility in the presence of methylated groups that enlarge the CD
cavity. Photostability assays indicated that RM-β-CD slowed down the
photodegradation of BNZ, compared to that of the “free’’ molecule,
making it more stable in the presence of light. The results of this study
on epimastigote forms of T. cruzi, DM28c clone, indicated that the
complexation of BNZ with RM-β-CD did not interfere with trypanocidal
activity, preserving the integrity of the molecule. The growth inhibition
performance of both was similar and dose- and time-dependent,
reaching 92% of growth inhibition at 0.2 mM. According to cytotoxicity
assay in mammalian cells, complexes exhibited minor cytotoxic effects
compared with the BNZ. It could be due to the higher hydrophilicity
properties of complexes compared to the free drug. As reported, lipo-
philic substances are capable to interact and greatly modify the cell
membranes producing, therefore, important damages to the cells. Thus,
the authors concluded that CD inclusion complexes are a promising
alternative for the development of a liquid formulation, safe and stable
of BNZ in order to treat the Chagas disease (Lyra et al., 2012). In other
study, Leonardi et al. (2013) investigated the influece of stoichiometric
and non-stoichiometric BNZ-CDs complexes on the solubility, dissolu-
tion rate and drug bioavailability. The complexes were formulated at
1:1 and 1:2 drug-CD molar ratio, by the solvent evaporation technique
using water and ethanol as solvents. It was found that BNZ solubility
increased by increasing the carrier concentration, suggesting a forma-
tion of complexes with a stoichiometry of 1:1. BNZ solubility increased
from 0.70mM to nearly 2.90mM by increasing CD ratio, probably due
to intermolecular hydrogen bonds between the host and the drug,
which could lead to the formation of water-soluble complexes. Parti-
cularly, Me-β-CD was the most effective carrier to enhance the drug
solubility compared to HP-β-CD and β-CD carriers. This finding could
be due to the higher hydrophobic character of the CD cavity by the
presence of methyl groups, which could increase the affinity with hy-
drophobic drugs. Dissolution studies showed that both the type and
ratio of the carrier had a direct impact on the BNZ release. At 10min,
21% of non-complexed BNZ was dissolved whereas BNZ-Me-b-CD
complexes dissolved 72% (1:1M ratio complexes) and 90% (1:2M ratio
complexes) of drug at the same time. Such differences could be due to
several factors including the affinity of the carrier by the drug, mod-
ification of the thermal behavior of BNZ after complexation, reduction
of the drug crystalline patters, and modification of the morphology, size
and surface of drug particles when complexed. As described by Carrier
et al. (2007), the complexation of drugs may increase or decrease its
absorption and further bioavailability, having a direct impact on the
biological activity. In this case, in-vivo studies demonstrated that no
significant differences were observed in the drug absorption from the
stoichiometric and non-stoichiometric BNZ complexes. In addition, it
was found that pharmacokinetic parameters showed that complexes of
Me-β-CD were the most effective to deliver BNZ. Overall, BNZ com-
plexed with CDs may be able to reduce drug lipophilicity and also
improve its oral absorption, confirming that this approach is valid for
the development of oral dosage forms.
Later, Vinuesa et al. (2017) developed hydroxypropyl-β-cyclodex-
trin (HP-β-CD) complexes loaded with BNZ by an antisolvent pre-
cipitation method with compressed CO2. Complexed drug was com-
pletely amorphous and showed homogeneous nanostructure revealed
by differential scanning calorimetry and scanning electron microscopy.
Cytotoxicity assay in mammalian cells (L 929 and Hep G2) showed that
complexes had a significantly lower toxicity than free BNZ. Results of
biological activity against epimastigotes of T. cruzi (CL strain, clone B5)
indicated that the IC50 of the inclusion system was higher that the IC50
of free BNZ, values being 18.4 ± 4.7 and 14.8 ± 4.9, respectively,
and with sonicated HP-β-CD a lower IC50 was obtained than with free
BNZ after sonication (16.7 ± 4.6 and 26.8 ± 1.6, respectively). In
addition, biological activity of nanostructured HP-β-CD against trypo-
mastigotes/amastigotes of T. cruzi had an IC50 of 4.0 ± 0 whereas the
IC50 of BNZ was 0.8 ± 0.4. Therefore, the adequate balanced anti-
trypanosomal/toxicity of these systems may offer improved ther-
apeutics for Chagas disease (Vinuesa et al., 2017).
Often the association of a third compound in these inclusion com-
plexes has demonstrated higher complexation efficiency. These systems
are denominated ternary complexes and generally are composed of a
drug, CDs, and a third component (Srivalli and Mishra, 2016). For ex-
ample, diverse polymers were used to modulate drug release from in-
clusion complexes with CDs. Soares-Sobrinho et al. (2012) also devel-
oped inclusion complexes by loading BNZ in binary systems with
randomly methylated-β-cyclodextrin (RM-β-CD) and in ternary systems
with hydrophilic polymers, HPMC or polyvinylpyrrolidone (PVP). After
selecting the type and concentration of polymer (0,1% HPMC), the
systems BNZ:RM-β-CD and BNZ:RM-β-CD:HPMC were obtained by two
methods, kneading and evaporation. The corresponding analysis of the
complexes suggested that the system with 1:0.17 proportion BNZ:RM-β-
CD was the most adequate for the development of a formulation. in vitro
dissolution assay showed the HPMC had not a significant influence on
the release of BNZ and would not justify its use since the percentage of
the drug dissolved was higher than 90% within 60min in binary sys-
tems. Regarding to methods, the systems obtained by evaporation en-
abled total dissolution of the BNZ at 60min with dissolution efficiency
after 15min (DE15) of 48.9. The systems obtained by kneading also
achieved satisfactory rates of dissolution with an average percentage of
94.4% of drug dissolved at 60min and DE15 value of 41.6. The
kneading process is the most commonly used in the pharmaceutical
industry since it has the advantages of being simple, high yielding and
easy to scale up. Therefore, the use of this method is justified, in view of
the possibility of scaling this up to industrial levels reducing the cost of
production of a formulation with low concentration of CD (Soares-
Sobrinho et al., 2012). Later, Sá-Barreto et al. (2013) were able to
control the release of BNZ from solid inclusion complexes with HP-β-CD
by using the hydrophilic hydroxypropyl methylcellulose (HPMC)
polymer. The evaluation of such ternary complexes showed that the
system containing HPMC presented a very slow dissolution rate, with a
dissolution efficiency at 30min (DE30) of only 11.4. It could be due to
when HPMC is in aqueous medium, a viscous gelatinous layer is
formed, which delays the release of the drug from the polymer matrix.
In contrast, the binary system without HPMC showed a dramatic im-
provement in drug dissolution rate compared to the dissolution rate of
free BNZ. The possibility of combining both binary and ternary com-
plexes in order to achieve an initial fast drug delivery followed by a
sustained release could be a strategy towards improving the drug
bioavailability (Sá-Barreto et al., 2013).
11. Future perspectives
The development of nanometric pharmaceutical systems represent
the latest approach to improve the chemotherapeutic action as well as
to avoid the undesirable biological effects of medicines. Specifically,
nanotechnology is, probably, the best alternative to provide new in-
sights on the treatment of Chagas disease. The particular properties of
nanostructures allow their application in different dosage forms ad-
ministered by oral route. However, one the main drawbacks of these
promising delivery systems are the physical and chemical stability is-
sues. Other limitations are the low encapsulation capacity, particle
aggregation and/or agglomeration, precipitation, and recrystallization
possess a remarkable impact on the release and permeability of drugs,
which can lead to final products with different quality attributes, in-
cluding low or erratic bioavailability and variable biological activity
(Flühmann et al., 2019).
Furthermore, the pathway to more rational pre-clinical studies and
further clinical applications is still far from being executed. To improve
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the clinical translation process from the bench to the bedside, it is
mandatory to address different experimental steps, including a detailed
evaluation of those nanosystems with the blood, tissues and organs of
non- infected and infected human host (Nehoff et al., 2014; Hua et al.,
2018). It is also important to consider that one of critical step related
with the development to “nano” drug delivery systems are the toxicity
issues. Handling materials in a nanometric scale for drug delivery may
result in the appearance of serious and/or unexpected side effects, due
to such nanomaterials are in the size range of biomacromolecules and
cells and may interact with them modifying negatively cell permeability
and/or affecting normal cellular functions (Septiadi et al., 2018). Then,
the corresponding nanocarriers might be inherently more toxic than the
original untreated materials. Taking into account, more efforts are
needed to prevent and detect both environmental impact and side ef-
fects in living organisms based on the manipulation of nanomaterials
and use of nanomedicines, respectively.
12. Conclusions
BNZ and NFX are the unique available treatments for Chagas dis-
ease, to date. Nevertheless, none of them are capable to cure the in-
fection in both phases of the disease. Additionally, high doses required
and long-term treatments as well as the existence of serious adverse
effects and drug-resistant parasites confirm an urgent need to develop
more innovative and effective chemotherapeutic alternative to treat,
successfully, Chagas disease.
In this regard, the purpose of this review was to summarize the
latest advances related with the application of nanotechnologies to
improve the delivery and biological activity of BNZ and NFX. Thus,
according to the literature, only two research works published in 1998
and 2002 explored the nanoencapsulation of NFX into poly-
ethylcyanoacrylate carrier. Since then, no any other work was pub-
lished, suggesting the lack of interest to find a more suitable formula-
tion of NFX against T. cruzi infection. On the other hand, a more
extensive research to develop novel BNZ delivery systems by means of
different nanocarriers is ongoing. Thus, the preparation of BNZ lipo-
somes was described for the first time in 2002 and, recently nano-
crystals, polymeric nanoparticles, and lipid nanostructures were de-
veloped. Some of these new approaches exhibited a remarkable in-vitro
and in-vivo efficacy in infected murine model indicating that the ap-
plication of the detailed nanotechnologies may be an attractive ap-
proach to improve the solubility and dissolution of BNZ and NFX
leading to a potential reduction of the doses and, perhaps, novel
treatment schemes. Therefore, it would be possible to reduce the ap-
pearance or incidence of side effects, avoiding the interruption of the
treatment.
As demonstrated herein, BNZ and NFX nanostructures are novel
drug delivery systems, which have many advantages over the available
medicines, including their biocompatibility, biodegradability, superior
solubility and fast or controlled release profiles. In conclusion, the novel
strategies to improve the delivery of BNZ and NFX are crucial steps to
reach novel treatments with less side effects and with therapeutic ef-
ficacy in the chronic phase of the disease.
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